Intuitive Surgical

ISRG

Market cap $190B

Intuitive Surgical, Inc. (ISRG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Intuitive pre-announced sales results for Q4 today -- and growth is slowing down. Full-year and Q4 earnings results won't come out for another week.

These players each are leaders in their specialty areas and have generated billions of dollars in revenue. This list includes a biotech stock, a pharma player, and a medical device company.

Intuitive Surgical stock tumbled Wednesday after the robotic surgery giant issued a lackluster view for 2026 procedure growth.

SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

ISRG's da Vinci 5 begins international rollout, but pricing sensitivity, budgets, and reimbursement hurdles could slow adoption outside the United States.

ISRG is positioning da Vinci 5 as a TAM expander, targeting cardiac surgery long term while advancing near-term regulatory steps in general surgery.

Intuitive Surgical, Inc. dominates surgical robotics with an 80% global share and a robust, recurring-revenue business model anchored by the da Vinci platform. ISRG's installed base and procedure volumes continue double-digit growth, driven by superior clinical outcomes and high hospital switching costs. Despite premium valuation (forward P/E ~64), ISRG's pristine balance sheet, strong margins, and relentless innovation justify a long-term Buy rating.

The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $585.08, representing a -1.21% change from its previous close.

Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.